Associates of an Elevated Natriuretic Peptide Level in Stable Heart Failure Patients: Implications for Targeted Management

Table 1

Table of demographics and clinical parameters for total population and for the population split by median BNP of 165 pg/mL.

	All	BNP>165	BNP≤165	𝑃
Male	113 (63%)	56 (62%)	57 (64%)	0.92
Age (years)	71±12	75±11	67±13	<0.001
BMI (kg/m^2)	30±7	28±6	32±8	0.009
Systolic BP (mmHg)	131±19	131±20	131±19	0.90
Diastolic BP (mmHg)	71±11	70±12	72±11	0.21
Idiopathic	30 (19%)	6 (8%)	24 (28%)	0.003
Ischaemic	86 (54%)	50 (68%)	36 (42%)	0.003
Hypertension	51 (32%)	29 (39%)	22 (26%)	0.10
Valvular	18 (11%)	10 (13%)	8 (9%)	0.57
Biochemistry
BNP (pg/mL)	165 (71 : 325)	325 (231 : 516)	67 (27 : 115)	<0.001
Urea (mmol/L)	7.8 (6.1 : 11.4)	9.3 (7.3 : 12.8)	6.7 (5.3 : 8.9)	<0.001
Creatinine (mmol/L)	115 (94 : 145)	126 (103 : 157)	107 (87 : 133)	<0.001
Sodium (mmol/L)	138±3	138±3	138±3	0.36
Potassium (mmol/L)	4.4±0.4	4.4±0.3	4.4±0.4	0.54
Medications
Beta blocker	143 (90%)	68 (92%)	75 (88%)	0.61
ACEI/ARB	151 (95%)	70 (95%)	81 (95%)	0.87
Diuretics	131 (82%)	65 (88%)	66 (78%)	0.14
Aldosterone antagonist	27 (17%)	12 (16%)	15 (18%)	0.99

Values are mean ± standard deviation or median (interquartile range); BNP: B-type natriuretic peptide; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; BMI: body mass index; SBP/DBP: systolic and diastolic blood pressure.